Overview of positive news from listed companies on the evening of May 10 (with list)

Many listed companies on the Shanghai and Shenzhen stock exchanges released important announcements on the evening of May 10. The following is a summary of positive news:

ST Huaxing: Chairman and core management plan to increase company holdings by 5 million to 6 million yuan

ST Huaxing (600340) announced that the company’s chairman and core management plan to increase their holdings of the company’s shares within three months starting from May 11, 2026, by purchasing the shares through the Shanghai Stock Exchange system via centralized bidding transactions. No price range has been set for this increase. The total amount of the increase will be no less than 5 million yuan and no more than 6 million yuan.

Hanbang Gaoke: Subsidiary signs a 2.783 billion yuan contract for high-performance GPU equipment procurement and integrated maintenance services

Hanbang Gaoke (300449) announced that its wholly owned subsidiary, Beijing Hanbang Gaoke Digital Intelligence Technology Co., Ltd., signed the “High-Performance GPU Equipment Procurement and Integrated Maintenance Services Contract” with Beijing Qimingxing Han Technology Co., Ltd. (abbreviated as “Xinghan Technology”). The contract amount inclusive of tax is approximately 2.783 billion yuan; the contract amount exclusive of tax is approximately 2.463 billion yuan. This represents 1515.13% of the company’s audited operating revenue for 2025.

Fanfan Co.: Wins approximately 86.6412 million yuan in a State Grid bidding procurement project

Fanfan Co. (601700) announced that on May 7, State Grid Corporation of China released the “Bid Winning Announcement for the Second Round of Public Bidding Procurement of Equipment Materials for the 2026 Power Transmission and Transformation Projects” and the “Bid Winning Announcement for the First Round of Public Bidding Procurement of Equipment Materials Framework Agreement (Agreement Inventory) for the 2026 Power Transmission and Transformation Projects.” The company was the winning bidder for “Angle Steel Tower Package 3,” “Steel Pipe Tower Package 10,” “Angle Steel Tower Package 94,” and “Angle Steel Tower Package 25” in the above bid-winning announcements. The winning amount is approximately 86.6412 million yuan, accounting for approximately 2.91% of the company’s audited operating revenue for 2025.

Jintao Ling: Wins a project of about 232 million yuan

Jintao Ling (002081) announced that recently it received a “Winning Notice” issued by Binzhou Binke Real Estate Co., Ltd., and the company has been determined as the winning bidder for the indoor fine decoration supply and construction project of Weiqiao Guoke (Binzhou) Talent Community, which is invested in and developed by Binzhou Binke Real Estate Co., Ltd. The total winning amount is approximately 232 million yuan, accounting for 1.34% of the company’s audited operating revenue for 2025.

Fosun Pharma: Controlling subsidiary’s drug HLX05-N approved by the U.S. FDA for a clinical trial

Fosun Pharma (600196) announced that recently, its controlling subsidiary Shanghai Fosun Hanlin Biotech Co., Ltd. and its controlling subsidiaries received approval from the U.S. FDA (i.e., the U.S. Food and Drug Administration) to conduct a Phase I clinical trial of HLX05-N (i.e., recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer. HLX05-N is a biosimilar drug of cetuximab injection independently developed by the company and its controlling subsidiaries. It is planned for use in the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma.

Fosun Pharma: Controlling subsidiary’s drug receives EU approval for additional indications

Fosun Pharma (600196) announced that recently, its controlling subsidiary Shanghai Fosun Hanlin Biotech Co., Ltd. and its controlling subsidiaries’ self-developed sLuruli monoclonal antibody injection (EU trade name: Hetronifly®) received approval from the European Commission for the following two additional indications: 1. In combination with fluorouracil-based and platinum-based chemotherapy, for first-line treatment of adult patients with PD-L1 combined positive score (CPS) ≥5, unresectable locally advanced disease, recurrent or metastatic esophageal squamous cell carcinoma (ESCC); 2. In combination with carboplatin and pemetrexed, for first-line treatment of adult patients with unresectable locally advanced disease or metastatic non-squamous non-small cell lung cancer (nsNSCLC) that are negative for EGFR gene mutations and ALK or ROS1. Accordingly, these additional indications have been approved in all EU member states, as well as Iceland, Liechtenstein, and Norway (countries in the European Economic Area).

(Source: Oriental Fortune Research Center)